CME QUESTIONS FOR JULY 2004 ISSUE OFTHE JOURNAL OF UROLOGY

1. METABOLIC RISK FACTORS AND THE IMPACT OF MEDICAL THERAPY ON THE MANAGEMENT OFNEPHROLITHIASIS IN OBESE PATIENTS (vol. 172, pp. 159–163)

The first line treatment of recurrent stone disease in obese patients is:

a) thiazidesb) allopurinolc) Thiolad) potassium citratee) acetohydroxamic acid

2. SEMINAL SPARING CYSTECTOMY AND ILEOCAPSULOPLASTY: LONG-TERM FOLLOWUP RESULTS (vol. 172,pp. 76–80)

Seminal sparing cystectomy consists of:

a) removing of the bladder and prostatic urethra with surrounding hypertrophic prostatic tissue, and preservation ofprostatic capsule, seminal vesicles, vas deferens and ampullae of the vasab) removing of the bladder with prostatic section at a supra-ampullar level, and preservation of seminal vesicles, vasdeferens and ampullae of the vasac) removing of the bladder with preservation of the whole prostate, seminal vesicles, vas deferens and ampullae of thevasad) removing of the bladder and prostate with preservation of seminal vesicles, deferens and ampullae of the vasae) removing of the bladder, prostate, seminal vesicles, vas deferens and ampullae of the vasa with preservation ofneurovascular bundles

3. PERCUTANEOUS NEPHROSCOPIC MANAGEMENT OF UPPER URINARY TRACT TRANSITIONAL CELLCARCINOMA: RECURRENCE AND LONG-TERM FOLLOWUP (vol. 172, pp. 66–69)

In a patient with a solitary tumor in the renal pelvis of 0.5 cm on excretory urography the best approach is:

a) percutaneousb) partial pyelectomyc) ureterorenoscopyd) nephroureterectomye) intrarenal bacillus Calmette-Guerin

4. URETHROPLASTY IN PATIENTS OLDER THAN 65 YEARS: INDICATIONS, RESULTS, OUTCOMES ANDSUGGESTED TREATMENT MODIFICATIONS (vol. 172, pp. 201–203)

The most frequent complication occurring after urethroplasty in older men is:

a) bladder outlet obstruction from benign prostatic hyperplasiab) myocardial infarctionc) impotenced) wound dehiscencee) renal insufficiency

5. THE NATURAL HISTORY OF ANDROGEN INDEPENDENT PROSTATE CANCER (vol. 172, pp. 141–145)

The most important variable in predicting the development of cancer specific symptoms and eventual cancer death inmen with androgen independent prostate cancer is:

a) Gleason sum of original tumorb) nadir prostate specific antigen level on androgen deprivation therapyc) prostate specific antigen doubling timed) presence of bone metastasese) time to prostate specific antigen recurrence following treatment with androgen deprivation therapy

The Journal of Urology®

Volume 172, Number 1, July 2004

423